Great Pricing
FAST and FREE Shipping
99+% Purity Verified by Independent US Laboratories

Note: This article is for educational and informational purposes only. Any studies referenced relate solely to laboratory and scientific models. Peptides discussed here are for Research Use Only. They are not approved drugs, supplements, or cosmetic products and are not for human or veterinary use.

Retatrutide has attracted significant attention because of the substantial weight reduction observed in clinical trials. But one of the most common questions surrounding the compound is also one of the most important: What doses of retatrutide have actually been studied?

Because retatrutide remains investigational, there is currently no FDA-approved retatrutide dosing schedule. However, clinical trials provide detailed information about the doses researchers have evaluated, how participants progressed toward higher target doses and how dosing affected both results and tolerability.

The research shows that retatrutide has generally been administered once weekly, with target doses ranging from 1 mg to 12 mg in Phase 2 research. More recent Phase 3 trials have focused primarily on target doses of 4 mg, 9 mg and 12 mg.

Just as importantly, researchers have learned that how participants reach those doses matters. Gradual dose escalation has become a central part of the retatrutide research program.

What Is Retatrutide?

Retatrutide is an investigational metabolic compound designed to activate three hormone receptors:

• GLP-1
• GIP
• Glucagon

This three-receptor mechanism has led retatrutide to be described as a triple-receptor agonist.

Semaglutide primarily targets GLP-1 receptors, while tirzepatide targets GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activity, which researchers believe may contribute to its effects on appetite, energy expenditure and fat metabolism.

For more background on these pathways, see our guide to the differences between GLP-1, GLP-2 and GLP-3-type compounds.

You can also explore why the additional glucagon activity has generated so much interest in Retatrutide and the Rise of the “Triple G”.

What Retatrutide Doses Were Studied in Phase 2?

One of the most important retatrutide studies was the Phase 2 obesity trial, which evaluated multiple doses over 48 weeks.

Researchers studied weekly retatrutide target doses of:

• 1 mg
• 4 mg
• 8 mg
• 12 mg

Importantly, not every participant immediately began at the assigned target dose.

Researchers tested different starting doses and escalation strategies, particularly among participants assigned to the higher-dose groups.

The basic Phase 2 dose structure looked like this:

Testing multiple starting doses helped researchers examine an important question: could slower escalation improve tolerability and decrease retatrutide side effects while still allowing participants to reach higher target doses?

The answer appears to have influenced the design of later retatrutide trials.

How Was Retatrutide Increased During the Phase 2 Trial?

Participants assigned to higher target doses did not immediately receive those doses.

Instead, researchers gradually increased the amount administered over time.

This process is commonly called dose escalation or titration.

For the higher-dose groups, doses were generally increased at four-week intervals until participants reached their assigned target dose.

This allowed researchers to evaluate not only how different target doses performed, but also whether starting at a lower dose affected tolerability.

The results suggested that it did.

Participants who started at 2 mg generally experienced fewer gastrointestinal side effects from retatrutide than participants who began at 4 mg.

That finding became particularly important as the retatrutide clinical development program moved into larger Phase 3 trials.

What Retatrutide Doses Are Being Studied in Phase 3?

The Phase 3 TRIUMPH program has focused on several target doses, particularly:

• 4 mg
• 9 mg
• 12 mg

TRIUMPH-1 provides an especially useful example of how the dosing strategy evolved.

Rather than using different starting doses, participants receiving retatrutide began at 2 mg once weekly.

Their doses were then gradually increased approximately every four weeks until they reached their assigned target dose.

The general Phase 3 dosing structure can be summarized as follows:

This progression demonstrates how lessons learned during Phase 2 research influenced later trial design.

What Did the Phase 3 Retatrutide Dosing Schedule Look Like?

In TRIUMPH-1, participants receiving retatrutide began at 2 mg weekly and moved through intermediate doses before reaching the higher target doses.

The dose-escalation approach can be illustrated approximately as:

Dose increases occurred at approximately four-week intervals.

This is an important distinction when interpreting retatrutide research.

A participant assigned to 12 mg was not simply given 12 mg at the beginning of the trial. Researchers progressively increased the dose over a period of months.

The escalation strategy allows researchers to study higher target doses while attempting to improve tolerability.

Why Did Researchers Start Retatrutide at 2 mg?

The choice of a 2 mg starting dose appears to reflect findings from earlier research.

During the Phase 2 obesity trial, researchers found that gastrointestinal adverse events were partially reduced when participants began at 2 mg rather than 4 mg.

The most commonly reported adverse events included:

• Nausea
• Diarrhea
• Vomiting
• Constipation

These effects occurred primarily during the period when doses were being increased.

Rather than abandoning higher target doses, researchers refined how participants progressed toward them.

This relationship between dose escalation and tolerability is examined in detail in our companion article, Retatrutide Side Effects: What the Research Says About Safety and Tolerability.

Does a Higher Retatrutide Dose Produce Greater Weight Reduction?

The clinical research has demonstrated a clear dose-response relationship.

In the Phase 2 obesity trial, higher retatrutide target doses generally produced greater average weight reduction.

At 48 weeks, average body-weight changes were approximately:

The higher-dose groups produced substantially greater average weight reduction than the 1 mg group.

These findings helped establish retatrutide as one of the most closely watched compounds in metabolic research.

For a broader look at why the compound’s results have attracted so much attention, read Why Retatrutide Is Becoming a Standout Metabolic Peptide.

What Did Phase 3 Show About Retatrutide Dose and Weight Loss?

The Phase 3 TRIUMPH-1 results strengthened the evidence for a dose-response relationship.

At 80 weeks, average body-weight reductions were:

The 12 mg group produced the greatest average reduction.

Participants receiving 12 mg lost an average of approximately 70.3 pounds during the 80-week period.

These results also demonstrate why dosing cannot be separated from the broader question of retatrutide’s metabolic effects.

Researchers are investigating not only total weight reduction, but also what happens to fat mass and lean tissue as body weight decreases. Our article Retatrutide and Lean Muscle Preservation explores this aspect of the research.

Is 12 mg the Maximum Retatrutide Dose?

A 12 mg once-weekly target dose has been extensively studied in retatrutide obesity research and has been the highest assigned target dose in major Phase 2 and Phase 3 obesity trials.

However, it is important to distinguish between a clinical trial target dose and an approved maximum dose.

Retatrutide remains investigational.

There is currently no FDA-approved retatrutide prescribing information establishing a recommended starting dose, maintenance dose or maximum dose.

The 12 mg figure therefore describes a dose used in clinical research, not an approved dosing recommendation.

Does Everyone in a Retatrutide Trial Reach the Highest Dose?

No.

Clinical trials are designed around assigned target doses, but tolerability can affect whether individual participants remain at those doses.

Researchers monitor adverse events throughout treatment.

This is particularly relevant because gastrointestinal effects tend to become more common at higher doses.

In TRIUMPH-1, adverse-event-related treatment discontinuation occurred in approximately:

This demonstrates why researchers evaluate both effectiveness and tolerability when studying different doses.

Even in the highest-dose group, however, nearly nine out of ten participants did not discontinue because of an adverse event.

How Often Is Retatrutide Administered in Clinical Trials?

Retatrutide has generally been administered once weekly in major clinical trials.

The compound has been studied as a subcutaneous injection.

This weekly administration schedule is similar to the schedules used for several other incretin-based compounds.

However, retatrutide’s mechanism is different because it simultaneously activates GLP-1, GIP and glucagon receptors.

For a closer look at how retatrutide differs from a dual-receptor compound, see Retatrutide vs Tirzepatide: A New Frontier in Weight Loss Research.

Why Doesn’t Retatrutide Have an Official Dosing Schedule?

Retatrutide does not have an official dosing schedule because it has not been approved by the FDA.

Clinical trials are designed to determine questions such as:

• Which doses produce meaningful effects?
• How should doses be escalated?
• Which doses provide the best balance between efficacy and tolerability?
• What adverse events occur at different dose levels?
• How do different populations respond?

Until the clinical development program and regulatory review are complete, doses discussed in retatrutide research should be understood as experimental clinical trial protocols rather than prescribing recommendations.

How Does Retatrutide Dosing Compare With Tirzepatide?

Retatrutide and tirzepatide are both administered once weekly in major clinical research and both use gradual dose escalation.

However, the compounds are not interchangeable.

Tirzepatide activates two receptors:

• GLP-1
• GIP

Retatrutide activates three:

• GLP-1
• GIP
• Glucagon

Because the compounds have different receptor profiles, the milligram amounts used for one compound cannot be directly translated into equivalent amounts of the other.

A 10 mg dose of one compound should not be assumed to have the same biological effect as 10 mg of another.

For a more complete comparison, see Retatrutide vs Tirzepatide.

Why Higher Retatrutide Doses Are So Interesting to Researchers

One of the most striking findings from retatrutide research has been the continued weight reduction observed at higher target doses.

The Phase 2 trial showed progressively greater average weight reduction as doses increased from 1 mg to 4 mg, 8 mg and 12 mg.

Phase 3 research has reinforced that pattern.

The additional glucagon receptor activity may help distinguish retatrutide from earlier incretin-based compounds because glucagon signaling can influence energy expenditure and lipid metabolism.

This is one reason retatrutide has sometimes been referred to as a “Triple G” compound.

For a deeper explanation of this mechanism, read Retatrutide and the Rise of the “Triple G”.

What Have Clinical Trials Taught Us About Retatrutide Dosing?

Several important conclusions can be drawn from the research conducted so far:

• Retatrutide has generally been administered once weekly.
• Phase 2 obesity research evaluated target doses ranging from 1 mg to 12 mg.
• Phase 3 obesity research has focused heavily on 4 mg, 9 mg and 12 mg target doses.
• Later trials have generally started participants at 2 mg rather than immediately administering higher target doses.
• Doses have been increased gradually, generally at approximately four-week intervals.
• Higher doses have generally produced greater average weight reduction.
• Starting dose and escalation speed can influence gastrointestinal tolerability.
• There is currently no FDA-approved retatrutide dosing schedule.

Taken together, the research demonstrates that retatrutide dosing is about more than simply identifying the highest dose that produces an effect.

Researchers are studying the relationship between starting dose, escalation, target dose, effectiveness and tolerability.

The Bottom Line

Retatrutide clinical trials have provided an increasingly detailed picture of how the compound has been dosed in research.

Phase 2 obesity research evaluated weekly target doses of 1 mg, 4 mg, 8 mg and 12 mg. Later Phase 3 research has focused primarily on 4 mg, 9 mg and 12 mg target doses.

Perhaps just as important as the target doses themselves is how researchers reached them.

Later trials have generally started participants at 2 mg once weekly and gradually increased the dose at approximately four-week intervals. This approach reflects earlier findings suggesting that lower starting doses can improve gastrointestinal tolerability.

Higher target doses have generally produced greater average weight reduction, with the 12 mg group in TRIUMPH-1 averaging a 28.3% reduction in body weight at 80 weeks.

At the same time, researchers continue to evaluate the balance between higher-dose effectiveness and tolerability.

For more on that relationship, read Retatrutide Side Effects: What the Research Says About Safety and Tolerability. You can also explore why retatrutide has become a standout area of metabolic research and the research into retatrutide and lean muscle preservation.

Because retatrutide remains investigational, these clinical trial protocols should not be interpreted as an approved dosing schedule or instructions for self-administration.